Stoke Therapeutics, Inc. (STOK) Q2 FY26 Earnings Call

Emperor remains on schedule with 162 enrolled and no discontinuations, but pivotal efficacy data are not expected until Q3 2027 [3].

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-03
Length63 minutes
EPS$-0.93
EPS consensus$-0.82
Revenue$9.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All STOK earnings ยท Back to STOK overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.